首页> 外文OA文献 >Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry

【2h】

Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry

机译：与AbiraTerone醋酸盐加上泼尼松或泼尼松龙作为转移性阉割前列腺癌的第一或第二线治疗的现实世界的安全和疗效结果：来自前列腺癌登记处的数据

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Anders Bjartell; Nicolaas Lumen; Pablo Maroto; Thomas Paiss; Francisco Gomez-Veiga; Alison Birtle; Gero Kramer; Ewa Kalinka; Dominique Spaëth; Susan Feyerabend; Vsevolod Matveev; Florence Lefresne; Martin Lukac; Robert Wapenaar; Luis Costa; Simon Chowdhury;
展开▼
作者单位

展开▼
年度 2021
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO) [J] . Javier Puente, Aranzazu González-del-Alba, Núria Sala-Gonzalez, BMC Cancer . 2019,第1期

机译：AbiraTerone醋酸盐加上泼尼松与Cabazitaxel的疗效和安全性作为后续治疗转移阉割前列腺癌中的后续治疗：结果来自前瞻性观察研究（Capro）
2. Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer: a real-world retrospective study [J] . Jin-Ge Zhao, Jian-Dong Liu, Peng-Fei Shen, Asian journal of andrology . 2018,第6期

机译：现实世界的回顾性研究表明，在切换至二线非甾体类抗雄激素药物之前，不会影响醋酸阿比特龙对转移性去势抵抗性前列腺癌患者的治疗效果。
3. Prior switching to a second-line nonsteroidal antiandrogen does not impact the therapeutic efficacy of abiraterone acetate in patients with metastatic castration-resistant prostate cancer:a real-world retrospective study [J] . Jin-Ge Zhao, Hao Zeng, Jian-Dong Liu, 亚洲男性学杂志（英文版） . 2018,第006期

机译：改用二线非甾体类抗雄激素药不会影响醋酸阿比特龙对转移性去势抵抗性前列腺癌患者的治疗效果：一项现实世界的回顾性研究
4. Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer: A Decade of Progress and Ongoing Discoveries [C] . Leonel Hernez-Aya, Maha Hussain Genitourinary Cancers Symposium. . 2014

机译：转移激素敏感和阉割的前列腺癌：进步和持续发现的十年
5. Muscle Cross-Sectional Area Is Improved and Physical Funciton Is Maintained After Home-Based Exercise in Men with Metastatic Castration-Resistant Prostate Cancer Undergoing Androgen Deprivation Therapy [D] . Alzer, Mohamdod Saber. 2020

机译：改善肌横截面积，并且在具有转移阉割的前列腺癌接受雄激素剥夺治疗的男性中的男性锻炼之后，将物理静脉凝集维持
6. Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO) [O] . Javier Puente, Aranzazu González-del-Alba, Núria Sala-Gonzalez, 2019

机译：一线多西紫杉醇在转移性去势抵抗性前列腺癌后的后续治疗中醋酸阿比特龙联合泼尼松与卡巴他赛的疗效和安全性：前瞻性观察研究（CAPRO）的结果
7. Efficacy and safety of abiraterone acetate plus prednisone vs. cabazitaxel as a subsequent treatment after first-line docetaxel in metastatic castration-resistant prostate cancer: results from a prospective observational study (CAPRO) [O] . Javier Puente, Aranzazu González-del-Alba, Núria Sala-Gonzalez, 2019

机译：AbiraTerone醋酸盐加上泼尼松与Cabazitaxel的疗效和安全性作为后续治疗转移阉割前列腺癌中的后续治疗：结果来自前瞻性观察研究（Capro）

Real-World Safety and Efficacy Outcomes with Abiraterone Acetate Plus Prednisone or Prednisolone as the First- or Second-Line Treatment for Metastatic Castration-Resistant Prostate Cancer: Data from the Prostate Cancer Registry

著录项

引文网络

相似文献

相关主题

期刊订阅